Abstract 685P
Background
BL-M07D1 is an anti-HER2 antibody drug conjugate (ADC). It consists of a humanized anti-HER2 antibody, a cathepsin B cleavable linker, and a novel topoisomerase I inhibitor (Ed-04).
Methods
This study included subjects with locally advanced or metastatic HER2 expressing (positive/low) breast cancer (BC) and other solid tumors. For dose escalation (D-ESC), BL-M07D1 is planned to be administered at doses of 1.0mg/kg D1D8 Q3W or 2.6, 3.2, 3.8, 4.4, 5.0, 5.6, 6.2 mg/kg D1 Q3W. A subset of subjects were enrolled in the dose-expansion phase (D-EXP) at D1 Q3W regimens.
Results
As of May 1st, D-ESC has reached a dose of 5.0 mg/kg, with no observed dose limiting toxicities (DLTs).The maximum tolerated dose (MTD) was not reached. A total of 50 pts were treated with at least one dose, 19 pts in D-ESC and 31 in the D-EXP phase. The dose levels for expansion included 3.8, 4.4 and 5.0 mg/kg D1 Q3W. Among 50 pts,one received BL-M07D1 at 1.0 mg/kg on Day 1 and Day 8 every 3 weeks (D1D8 Q3W), while the remaining 49 subjects were treated with the drug on a Day 1 every 3 weeks (D1Q3W) schedule. The study enrolled 41 BC, 5 gastric cancer, 2 rectal cancer and 2 non-small cell lung cancer patients. The most common TRAEs (>10%, all grade /≥G3) were leukopenia (60%/13%), neutropenia (58%/21%), nausea (44%/0%), anemia (44%/0%), vomiting (25%/2%), lymphocyte count decreased (23%/8%), gamma-glutamyltransferase increased (21%/2%), asthenia (19%/0%), thrombocytopenia (19%/0%), decreased appetite (17%/0%), alopecia (17%/0%), aspartate aminotransferase increased (15%/0%). No ILD was observed. Twenty six subjects were evaluated for efficacy (i.e., at least one post-baseline tumor assessment). Updated efficacy and pharmacokinetic (PK) results will be presented at the conference. Table: 685P
ALL (n=26) | BC (n=23) | HER2+BC (n=15) | |
Median prior treatment lines (range) | 3 (1-13) | 3 (1-13) | 3 (1-13) |
Best overall response | |||
PR (cPR) | 11 (6) | 10 (6) | 9 (6) |
SD (with shrinkage) | 12 (8) | 11 (8) | 6 (4) |
PD | 3 | 2 | 0 |
ORR, % (95% CI) | 42.3 (23-63.1) | 43.5 (23.2-65.5) | 60 (32.3-83.7) |
DCR, % (95% CI) | 88.5 (69.9-97.6) | 91.3 (72-98.9) | 100% |
Conclusions
BL-M07D1 demonstrated encouraging efficacy in heavily pretreated HER2 expressing cancers, especially in HER2-positive BC. The safety profile showed adequate safety and tolerability.
Clinical trial identification
NCT05461768.
Editorial acknowledgement
Legal entity responsible for the study
SystImmune Inc.
Funding
Sichuan Baili Pharmaceutical Co., Ltd.
Disclosure
S. Xiao: Financial Interests, Personal, Full or part-time Employment: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.; Financial Interests, Personal, Stocks/Shares: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. H. Wang: Financial Interests, Personal, Full or part-time Employment: Systimmune Inc. H. Zhu: Financial Interests, Institutional, Full or part-time Employment: Systimmune Inc. M.S. Olivo: Financial Interests, Institutional, Officer, I'm the CMO of the company: SystImmune; Financial Interests, Institutional, Stocks/Shares: SystImmune. Y. Zhu: Financial Interests, Personal, Full or part-time Employment: SystImmune Inc; Financial Interests, Personal, Ownership Interest: SystImmune Inc., Baili Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17